Liječnički vjesnik, Vol. 137 No. 9-10, 2015.
Izvorni znanstveni članak
AUTOLOGOUS STEM CELL TRANSPLANTATION IN REFRACTORY OR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA – A SINGLE CENTRE EXPERIENCE
Vibor Milunović
Martina Bogeljić Patekar
Vinko Roso
Viktor Zatezalo
Bojana Aćamović Stipinović
Karla Mišura Jakobac
Njetočka Gredelj Šimec
Delfa Radić-Krišto
Ana Planinc-Peraica
Slobodanka Ostojić Kolonić
Sažetak
Autologous stem cell transplantation represents the gold standard in chemosensitive diffuse B large cell lymphoma in relapse or in refractory setting. The aim of this study was to present the outcome of peripheral autologous stem cell transplantation in patients with refractory or relapsed diffuse large B cell lymphoma. We retrospectively analysed the data of 62 patients, who underwent this procedure for the period 2000–2013. The majority of patients (71%) were treated with miniBEAM salvage chemotherapy and all received BEAM myeloablative protocol followed by the stem cell reinfusion. The overall response rate for autologous transplantation was 75.8%. Median overall survival was 37.2 months. Median event-free survival was 16.9 months. Factors associated with overall survival were state of disease prior to salvage chemotherapy, chemosensitivity of disease, International prognostic index, disease activity at the relapse, response to autologous transplantation and post-transplantation radiotherapy. The use of rituximab was not significantly correlated to the outcome. In this patient group autologous stem cell transplantation was found to be effective in achieving remission and survival showing the adequate role of this procedure in this clinical setting. We stress out that autologous stem cell transplantation was effective in 32.5% patients with chemorefractory disease after salvage therapy.
Ključne riječi
Lymphoma, large B-cell, diffuse – therapy; Hematopoietic stem cell transplantation; Transplantation, autologous; Antineoplastic combined chemotherapy protocols – therapeutic use; Antibodies, monoclonal, murinederived – therapeutic use; Salvage therapy; Recurrence; Survival analysis; Prognosis; Retrospective studies
Hrčak ID:
172718
URI
Datum izdavanja:
29.10.2015.
Posjeta: 3.325 *